

VisionOne™ demonstrates clinical-grade performance compared to perimetry gold-standard in new landmark study with University Hospital Bern

Lausanne, Switzerland — August 10, 2026.

A new prospective, single-centre observational study conducted at University Hospital Bern (Inselspital) demonstrates that VisionOne™ delivers clinical performance equivalent to the Octopus 900, a gold-standard stationary perimeter, across the full spectrum of glaucoma severity.

The study evaluated 73 patients (120 eyes) with mild, moderate, and severe glaucoma, each completing both examinations during the same visit. Researchers compared global indices (mean sensitivity and mean defect), pointwise sensitivity, total deviation, test duration, reliability metrics, and patient comfort.

Key findings

- Excellent agreement between VisionOne™ and the Octopus 900 across all stages of glaucoma.
- Excellent correlation for the global indices mean sensitivity and mean defect ($p = 0.97$, $p < 0.0001$).
- Strong spatial correlation for pointwise sensitivity and total deviation ($p = 0.88$ – 0.89).
- Agreement remained consistently high even in advanced glaucoma, a patient population that has been largely underrepresented in previous VR perimeter studies.
- Comparable examination times (6.3 vs. 6.5 minutes).
- Equivalent reliability indices.
- No patient discontinuing the examination.

Clinical significance: addressing the limitation of VR perimetry

This independent validation from University Hospital Bern represents a major milestone for PeriVision and VisionOne™. As Dr. Serife Kucur, CTO & co-founder of PeriVision, explains: “One of the main concerns surrounding virtual reality perimetry has been its limited ability to accurately assess patients with advanced glaucoma. This study directly addresses that question: we demonstrated that VisionOne™ maintains excellent agreement with the gold standard across the entire disease spectrum, including advanced cases.”

By combining:

- clinical performance equivalent to gold-standard stationary perimeters,
- a high degree of automation,
- a compact footprint,

- an intuitive user interface, and
- outstanding workflow efficiency,

VisionOne™ offers a compelling next-generation alternative to conventional automated perimetry for routine clinical practice.




Image: correlations of global indices mean sensitivity and mean defect from the study.

The full study can be accessed via [Ophthalmology Science](https://doi.org/10.1016/j.xops.2026.101314) (Colmenar Herrera, M., Hsin-Yang, C., Häner, N., Kucur Ergünay, S. S., Sznitman, R., & Zinkernagel, M. S. (2026). Evaluation of a Head-Mounted Virtual Reality Perimeter Compared with Stationary Perimeters across All Stages of Glaucoma. *Ophthalmology Science*, 6(9). <https://doi.org/10.1016/j.xops.2026.101314>).

Commercial traction

Since the release of VisionOne™ VFT, the certified product version incorporating our adaptive stimulus modulation method validated in this study, earlier this year, PeriVision has seen strong commercial traction across the EU, UK and US where it holds all relevant regulatory certifications.

To learn more about our customers and use cases, check out our case studies, e.g. a [Swiss ophthalmology clinic](#), a [UK optometry practice](#), and a [US decentralised clinical trial pilot](#).

To experience VisionOne™ live, join us at the Imaging and Perimetry Society conference in Bern between Aug 18-21, 2026: [IPS Bern 2026](#).

About PeriVision SA

PeriVision is a Swiss medtech company founded in 2022 as a spin-off from the University of Bern. The company develops a AI- and VR-powered vision testing platform with a first focus on visual field testing across glaucoma, retinal disease, and neuro-ophthalmology. Its flagship product, VisionOne™ VFT, enables clinical-grade perimetry on commercial VR headsets, combining AI-guided test algorithms, automated patient guidance, and cloud-based reporting. The company has won multiple awards such as the EIT Health Wild Card (2021) or the Switzerland TOP100 Startups and received several research grants from the Swiss federal government.

For more information about PeriVision and VisionOne™, please visit www.perivision.com or contact info@perivision.com.